Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143


Honokiol enhances paclitaxel efficacy in multi-drug resistant human cancer model through the induction of apoptosis.

Wang X, Beitler JJ, Wang H, Lee MJ, Huang W, Koenig L, Nannapaneni S, Amin AR, Bonner M, Shin HJ, Chen ZG, Arbiser JL, Shin DM.

PLoS One. 2014 Feb 25;9(2):e86369. doi: 10.1371/journal.pone.0086369. eCollection 2014.


Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.

Leeman-Neill RJ, Cai Q, Joyce SC, Thomas SM, Bhola NE, Neill DB, Arbiser JL, Grandis JR.

Clin Cancer Res. 2010 May 1;16(9):2571-9. doi: 10.1158/1078-0432.CCR-10-0333. Epub 2010 Apr 13.


Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.

Liu H, Zang C, Emde A, Planas-Silva MD, Rosche M, Kühnl A, Schulz CO, Elstner E, Possinger K, Eucker J.

Eur J Pharmacol. 2008 Sep 4;591(1-3):43-51. doi: 10.1016/j.ejphar.2008.06.026. Epub 2008 Jun 12.


The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis.

Raja SM, Chen S, Yue P, Acker TM, Lefkove B, Arbiser JL, Khuri FR, Sun SY.

Mol Cancer Ther. 2008 Jul;7(7):2212-23. doi: 10.1158/1535-7163.MCT-07-2409.


Honokiol synergizes chemotherapy drugs in multidrug resistant breast cancer cells via enhanced apoptosis and additional programmed necrotic death.

Tian W, Deng Y, Li L, He H, Sun J, Xu D.

Int J Oncol. 2013 Feb;42(2):721-32. doi: 10.3892/ijo.2012.1739. Epub 2012 Dec 14.


Cytotoxicity of the bisphenolic honokiol from Magnolia officinalis against multiple drug-resistant tumor cells as determined by pharmacogenomics and molecular docking.

Saeed M, Kuete V, Kadioglu O, Börtzler J, Khalid H, Greten HJ, Efferth T.

Phytomedicine. 2014 Oct 15;21(12):1525-33. doi: 10.1016/j.phymed.2014.07.011. Epub 2014 Aug 28.


Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1.

Rajendran P, Li F, Shanmugam MK, Vali S, Abbasi T, Kapoor S, Ahn KS, Kumar AP, Sethi G.

J Cell Physiol. 2012 May;227(5):2184-95. doi: 10.1002/jcp.22954.


Chamaejasmin B exerts anti-MDR effect in vitro and in vivo via initiating mitochondria-dependant intrinsic apoptosis pathway.

Wang YJ, Li Q, Xiao HB, Li YJ, Yang Q, Kan XX, Chen Y, Liu XN, Weng XG, Chen X, Cai WY, Guo Y, Huang HF, Zhu XX.

Drug Des Devel Ther. 2015 Sep 22;9:5301-13. doi: 10.2147/DDDT.S89392. eCollection 2015.


Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.

Koo JS, Choi WC, Rhee YH, Lee HJ, Lee EO, Ahn KS, Bae HS, Ahn KS, Kang JM, Choi SU, Kim MO, Lu J, Kim SH.

Life Sci. 2008 Nov 21;83(21-22):700-8. doi: 10.1016/j.lfs.2008.09.009. Epub 2008 Sep 24.


Targeting the intrinsic inflammatory pathway: honokiol exerts proapoptotic effects through STAT3 inhibition in transformed Barrett's cells.

Yu C, Zhang Q, Zhang HY, Zhang X, Huo X, Cheng E, Wang DH, Arbiser JL, Spechler SJ, Souza RF.

Am J Physiol Gastrointest Liver Physiol. 2012 Sep 1;303(5):G561-9. doi: 10.1152/ajpgi.00033.2012. Epub 2012 Jun 28.


Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer.

Milane L, Duan Z, Amiji M.

PLoS One. 2011;6(9):e24075. doi: 10.1371/journal.pone.0024075. Epub 2011 Sep 8.


Calpain/SHP-1 interaction by honokiol dampening peritoneal dissemination of gastric cancer in nu/nu mice.

Liu SH, Wang KB, Lan KH, Lee WJ, Pan HC, Wu SM, Peng YC, Chen YC, Shen CC, Cheng HC, Liao KK, Sheu ML.

PLoS One. 2012;7(8):e43711. doi: 10.1371/journal.pone.0043711. Epub 2012 Aug 24.


Honokiol augments the anti-cancer effects of oxaliplatin in colon cancer cells.

Hua H, Chen W, Shen L, Sheng Q, Teng L.

Acta Biochim Biophys Sin (Shanghai). 2013 Sep;45(9):773-9. doi: 10.1093/abbs/gmt071. Epub 2013 Jun 19.


Down-regulation of c-Src/EGFR-mediated signaling activation is involved in the honokiol-induced cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells.

Park EJ, Min HY, Chung HJ, Hong JY, Kang YJ, Hung TM, Youn UJ, Kim YS, Bae K, Kang SS, Lee SK.

Cancer Lett. 2009 May 18;277(2):133-40. doi: 10.1016/j.canlet.2008.11.029. Epub 2009 Jan 9.


Elimination of cancer stem-like cells and potentiation of temozolomide sensitivity by Honokiol in glioblastoma multiforme cells.

Lai IC, Shih PH, Yao CJ, Yeh CT, Wang-Peng J, Lui TN, Chuang SE, Hu TS, Lai TY, Lai GM.

PLoS One. 2015 Mar 12;10(3):e0114830. doi: 10.1371/journal.pone.0114830. eCollection 2015.


Synergistic antitumor effects of liposomal honokiol combined with adriamycin in breast cancer models.

Hou W, Chen L, Yang G, Zhou H, Jiang Q, Zhong Z, Hu J, Chen X, Wang X, Yuan Y, Tang M, Wen J, Wei Y.

Phytother Res. 2008 Aug;22(8):1125-32. doi: 10.1002/ptr.2472.


Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol.

Xu D, Lu Q, Hu X.

Cancer Lett. 2006 Nov 18;243(2):274-80. Epub 2006 Jan 10.


Honokiol inhibits the growth of head and neck squamous cell carcinoma by targeting epidermal growth factor receptor.

Singh T, Gupta NA, Xu S, Prasad R, Velu SE, Katiyar SK.

Oncotarget. 2015 Aug 28;6(25):21268-82.


Combinational delivery of hydrophobic and hydrophilic anticancer drugs in single nanoemulsions to treat MDR in cancer.

Ma Y, Liu D, Wang D, Wang Y, Fu Q, Fallon JK, Yang X, He Z, Liu F.

Mol Pharm. 2014 Aug 4;11(8):2623-30. doi: 10.1021/mp400778r. Epub 2014 Apr 21.


Honokiol: a novel natural agent for cancer prevention and therapy.

Arora S, Singh S, Piazza GA, Contreras CM, Panyam J, Singh AP.

Curr Mol Med. 2012 Dec;12(10):1244-52. Review.

Supplemental Content

Support Center